Oncoinvent ASA · OSL:ONCIN
Oncoinvent ASA — Investor Presentation (January 2024)
24 slides from Oncoinvent ASA's investor presentation, January 2024
Slide 1: Corporate Presentation
Corporate Presentation Developing a New Standard Therapy for Peritoneal Carcinomatosis (PC) with a local, receptor independent, radiopharmaceutical technology Anders Mansson, CEO
Slide 2: Oncoinvent: Investment Opportunity
Oncoinvent: Investment Opportunity Radiopharma hot-spot 1 Rapidly growing development area in oncology, substantial interest from investors and Big Pharma. 1 Experienced Leadership 2 Founders and management of Oncoinvent have a proven track record of developing a 2 radiopharmaceutical asset and brin
Slide 3: Radiopharmaceuticals Market Opportunity in Oncology - Investments
Radiopharmaceuticals is a lucrative and untapped Market Opportunity in Oncology - Investments • Radiopharmaceuticals have seen a recent surge of financings and acquisitions, creating a new attractive hot spot in oncology • The space is projected to experience continued growth and is positioned to su
Slide 4: Radiopharmaceuticals Market Opportunity in Oncology - Acquisitions
Radiopharmaceuticals is a lucrative and untapped Market Opportunity in Oncology - Acquisitions • Radiopharmaceuticals have seen a recent surge of financings and acquisitions, creating a new attractive hot spot in oncology • The space is projected to experience continued growth and is positioned to s
Slide 5: Experienced Developers in Innovative Radiopharmaceuticals
Experienced Developers in Innovative Radiopharmaceuticals Radiochemistry and Preclinical Expertise Encouraging Clinical Data and Upcoming Milestones Expert founders and management with decades of experience in developing alpha-emitting therapies for Clinical studies of Radspherin demonstrate excelle
Slide 6: Leadership Team Experienced in Building Companies and Bringing Radiopharmaceutical Therapy to Market
Leadership Team Experienced in Building Companies and Bringing Radiopharmaceutical Therapy to Market Anders Mansson Gro Hjellum Kari Myren Tore Kvam Chief Executive Officer Chief Operations Officer Chief Medical Officer Chief Financial Officer 6
Slide 7: Body Cavity Targeting - Peritoneal Carcinomatosis
Body Cavity Targeting - Peritoneal Carcinomatosis - A multiple cancer type disease area with a significant unmet medical need • Tumors of the peritoneum are most frequently Secondary extraperitoneal origin Secondary intraperitoneal origin caused by metastases from other primary Lung cancer Cholangio
Slide 8: Peritoneal Carcinomatosis – Room for Further Expansion
Peritoneal Carcinomatosis – Room for Further Expansion - Addressable market, beyond ph3 target, with significant unmet medical need Long-term survival rates of patients with PC Five-year survival rates in ovarian cancer2 by disease stage of colorectal origin1 90% 78% 70% 39% 36% 24% 17% 1 year 3 yea
Slide 9: Clinical Administration of Radspherin
Clinical Administration of Radspherin® - Delivering highly effective receptor-independent alpha-therapy directly to target area • A catheter is left after Cytoreductive Surgery (CRS) • Through that catheter a single dose of Radspherin® microparticles, dispersed in a solution, are injected directly i
Slide 10: Radspherin for the Treatment of Peritoneal Metastasis
Radspherin® for the Treatment of Peritoneal Metastasis - Delivering highly effective receptor independent alpha-therapy directly to target area • Non-systemic, single-dose, intraperitoneal Radspherin® aims to eliminate residual micro-metastases after cytoreductive surgery and thus prolong disease-fr
Slide 11: Radspherin - Clinical Development
Radspherin® - Clinical Development - Clinical dose established, enrollment to phase 2a in completion • Two Phase 1/2a studies - assessing dose, safety and tolerability, dosimetry and signal of efficacy of intraperitoneal Radspherin • Oslo/Norway(PI: Yun Wang) RAD-18-001: Ovarian/fallopian tube cance
Slide 12: Radspherin Robust Safety Profile
Radspherin® Robust Safety Profile - Well tolerated and minimal organ toxicity • No dose limiting toxicities observed at any dose level Well tolerated and considered safe to use • Well tolerated with only grade 1-2 events reported as possibly related to Radspherin® Clinically relevant dose determined
Slide 13: Clinical Phase 1/2a
Clinical Phase 1/2a - No peritoneal recurrences in recommended dose group in first cohort • Expected median time to progression after CRS-HIPEC is around 12 months • Meaning that 50 % of patients are expected to have recurred at 12 months 15-months safety and efficacy 18-months safety and efficacy p
Slide 14: Radspherin - Local & Overall DFS Plotting in CRC
Radspherin® - Local & Overall DFS Plotting in CRC - 18 months interim efficacy analysis phase 1/2a (n=22) • Disease-free survival at 18 months after the addition of 7 MBq Radspherin® to CRS-HIPEC was 67 % (n=12) Kaplan-Meyer curve of local disease-free survival Kaplan-Meyer curve of overall disease-
Slide 15: Radiopharmaceuticals Manufacturing Excellence
Radiopharmaceuticals Manufacturing Excellence • Reliable supply of the starting-material, radioisotope, Thorium-228. In- house production of Radium-224. • Internal expertise in development, manufacturing and quality control of radiopharmaceuticals. • In-house, state-of-the-art GMP production of Rads
Slide 16: Radspherin Clinical Development Plan
Radspherin® Clinical Development Plan 2024 2025 2026 2027 2028 2029 2030 Capital Need ca. 50 M USD, incl. full Ph2b cost Ph1/Ext OC 15 Follow-up Conditional Approval? Ph1/2a CRC 35 Follow-up Regular Ph3140/70 Ph2b/3 OC OC ~140/70 Recruitment Recruitment Ph3 OC ~140/70 Follow-up Approval? IND CTA Ph2
Slide 17: Identified Partner Candidates
Identified Partner Candidates CRC / Ovarian Cancer CRC / Ovarian Cancer & Radio pharmaceuticals Radiopharmaceuticals 17
Slide 18: Oncoinvent: Investment Opportunity
Oncoinvent: Investment Opportunity Radiopharma hot-spot 1 Rapidly growing development area in oncology, substantial interest from investors and Big Pharma. 1 Experienced Leadership 2 Founders and management of Oncoinvent have a proven track record of developing a 2 radiopharmaceutical asset and brin
Slide 19: Thank You
Thank You www.oncoinvent.com oncoinvent@oncoinvent.com
Slide 20: Appendix
Onc~e invent Appendix
Slide 21: Phase 2b Target Populations in Peritoneal Carcinomatosis
Phase 2b Target Populations in Peritoneal Carcinomatosis Peritoneal Carcinomatosis Ovarian Ovariancancer cancer Colorectal cancer ~4 000 pat/year ~20 000 pat/year Populations in Ph 2b HRD-negative subgroup with Adjuvant to CRS/HIPEC pre-operative chemotherapy Median PFS ~12 months Median PFS ~12 mon
Slide 22: Total Target Populations
Total Target Populations Peritoneal Carcinomatosis Other peritoneal and other body cavity Ovarian cancer Colorectal cancer Gastric cancer lesions (Bladder, Pleura…) ~4 000 pat/year ~20 000 pat/year Populations in Ph 2b ~ 4 000 - 8 000 pat/year ~20 000 pat/year Populations in Ph 3 / MA Same as Ph2b S
Slide 23: Radspherin Radiopharmaceutical Pricing Benchmarks
Radspherin® Radiopharmaceutical Pricing Benchmarks Product PFS Benefit OS Benefit Price • Radspherin® has a targeted PFS Xofigo N/A 3.6 m USD 69.000 improvement of 12 months Lutathera 8.5 m N/A USD 190.000 and a minimum acceptable profile of 6 months. Pluvicto N/A 4.0 m USD 255.000 PFS = Progression
Slide 24: Key Tenets of an Oncoinvent Business Case
Key Tenets of an Oncoinvent Business Case • Targeted Patient Population: 24.000 eligible patients per year (US & Europe) • CRC: 20.000 eligible patients (based on Phase 2b target only) • Ovarian Cancer: 4.000 eligible Patients (based on conservative, no extension, Phase 2b target only) Note that thi